Anavex Life Sciences Corp. (AVXL)
Summary
Anavex Life Sciences Corp. (AVXL) Discusses Board Misalignment, Leadership Concerns, and Strategic Changes for Company Turnaround Transcript
Anavex Life Sciences Corp. (AVXL) Discusses Board Misalignment, Leadership Concerns, and Strategic Changes for Company Turnaround Transcript
Anavex Life Sciences Corp. (AVXL) Discusses Clinical Development Strategy and Path Forward for CNS Indications Prepared Remarks Transcript
Anavex Life Sciences Corp. (AVXL) Discusses Clinical Development Strategy and Path Forward for CNS Indications Prepared Remarks Transcript
Anavex Life Sciences (AVXL) Upgraded to Buy: Here's What You Should Know
Anavex Life Sciences (AVXL) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Anavex Life Sciences Corp. Investors
| Name | Quantity | Cost | Value | Profit ($) | Gain (%) |
|---|---|---|---|---|---|
 Curtis Ellergodt Rothschild Investment LLC | 723 | $2,819.89 | $1,077.27 | -$1,742.62 | -61.8% |
| JD Jim Dushek HARBOUR INVESTMENTS Inc. | 850 | $4,501 | $1,266.5 | -$3,234.5 | -71.86% |
| MA mason adams PVG ASSET MANAGEMENT Corp. | 327,344 | $1.91M | $433,730.8 | -$1.47M | -77.27% |
| NA Nizar Araji National Bank Of Canada /FI/ | 1,000 | $8,900 | $1,480 | -$7,420 | -83.37% |
| BG Bart Gancher Intech Investment Management LLC | 21,533 | $206,049.14 | $31,868.84 | -$174,180.3 | -84.53% |
Anavex Life Sciences Corp. (AVXL) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Anavex Life Sciences Corp. ever had a stock split?
Anavex Life Sciences Corp. Profile
| Biotechnology Industry | Healthcare Sector | Terrie Kellmeyer CEO | NASDAQ (NGS) Exchange | 032797300 CUSIP |
| US Country | 34 Employees | - Last Dividend | 7 Oct 2015 Last Split | 2 Aug 2006 IPO Date |
Overview
Anavex Life Sciences Corp. is a clinical stage biopharmaceutical company focused on the development of novel therapeutics for the treatment of diseases affecting the central nervous system (CNS). With a strategic approach to leveraging its proprietary compounds, the company is at the forefront of addressing significant needs in the healthcare sector, particularly for conditions with limited or no effective treatments. Since its inception in 2004, Anavex has committed to exploring the potential of its drug candidates in treating a variety of CNS diseases, including Alzheimer's disease, Parkinson's disease, schizophrenia, and a spectrum of rare neurological disorders. Headquartered in New York, New York, Anavex is dedicated to advancing its clinical programs to bring innovative solutions to patients worldwide.
Products and Services
- ANAVEX 2-73
As the lead product candidate, ANAVEX 2-73 is currently under development for the treatment of Alzheimer's disease and Parkinson's disease. The therapeutic potential of ANAVEX 2-73 also extends to other central nervous system diseases, including rare diseases such as Rett syndrome - a severe neurological disorder, infantile spasms, Fragile X syndrome, and Angelman syndrome. ANAVEX 2-73's versatility demonstrates Anavex's commitment to addressing a broad range of neurological conditions.
- ANAVEX 3-71
Further in the pipeline, ANAVEX 3-71 is under clinical trials targeting the treatment of schizophrenia, frontotemporal dementia, and Alzheimer's disease. This drug candidate emphasizes Anavex's targeted therapeutic approach to CNS diseases, showcasing the company's innovative research in developing treatments for mental health conditions and neurodegenerative disorders.
- Preclinical Drug Candidates
- ANAVEX 1-41
Designed for the treatment of depression, stroke, and neurodegenerative diseases, ANAVEX 1-41 is at the preclinical stage, exploring its potential to address a wide array of CNS conditions. Its development underlines Anavex's commitment to expanding its treatment landscape to include mental health disorders and the consequences of cerebrovascular accidents.
- ANAVEX 1066
ANAVEX 1066 is being investigated for its potential in treating neuropathic and visceral pain. This candidate highlights Anavex's venture into pain management, an area of significant unmet medical need, particularly for patients suffering from chronic conditions.
- ANAVEX 1037
Targeting the treatment of prostate and pancreatic cancer, ANAVEX 1037 showcases Anavex Life Sciences Corp.'s expansion into oncology. Although at the preclinical stage, this candidate represents the company's efforts to explore therapeutic options beyond CNS disorders, offering potential new avenues in cancer treatment.
- ANAVEX 1-41
Contact Information
